Emerging research suggest Retatrutide , a dual agonist targeting both GLP-1 and glucose-dependent insulinotropic polypeptide , may represent a notable advancement for weight treatment. Early patient tests have shown substantial decreases in body fat , possibly outperforming current obesity therapies . However , more assessment is necessary to fully